Article

WITHDRAWN: Rucaparib in patients presenting a metastatic breast cancer with Homologous Recombination Deficiency, without germline BRCA1/2 mutation

2021-01-25

Abstract excerpt

<title>Abstract</title> <p>The authors have requested that this preprint be withdrawn due to author disagreement.</p>

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 7713fc64-fa75-5192-ac78-985980dee24b
DOI: 10.21203/rs.3.rs-78109/v2

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

WITHDRAWN: Rucaparib in patients presenting a metastatic breast cancer with Homologous Recombination Deficiency, without germline BRCA1/2 mutationDOI 10.21203/rs.3.rs-78109/v2Read

Rucaparib in patients presenting a metastatic breast cancer with homologous recombination deficiency, without germline BRCA1/2 mutation.Semantic proximity Read

Phase Ib SEASTAR Study: Combining Rucaparib and Sacituzumab Govitecan in Patients With Cancer With or Without Mutations in Homologous Recombination Repair Genes.Semantic proximity Read

[Novel target therapies used in breast cancer management].Semantic proximity Read

Olaparib monotherapy in advanced triple-negative breast cancer patients with homologous recombination deficiency and without germline mutations in BRCA1/2: The NOBROLA phase 2 studySemantic proximity Read

First evidence of olaparib maintenance therapy in patients with newly diagnosed homologous recombination deficient positive/BRCA wild-type ovarian cancer: real-world multicenter studySemantic proximity Read

Real-World Outcomes of CDK4/6 Inhibitors in Germline BRCA-Mutated Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: Turkish Oncology Group (TOG) StudySemantic proximity Read

Impact of homologous recombination deficiency on CDK4/6 inhibitor sensitivity in HR+/HER2-breast cancerSemantic proximity Read

Clinical and molecular characteristics of ARIEL3 patients who derived exceptional benefit from rucaparib maintenance treatment for high-grade ovarian carcinomaSemantic proximity Read

Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency (GeparOLA study)Semantic proximity Read

Evidence to date: talazoparib in the treatment of breast cancerSemantic proximity Read

Therapeutic options for triple-negative breast cancers with defective homologous recombination.Semantic proximity Read

Efficacy and Safety of Bevacizumab-Containing Therapy in Refractory Advanced Breast Cancer：A Retrospective StudySemantic proximity Read